Discussing Clinical and Payer Insights to Encourage the Adoption of Oncology Biosimilars into Practice

Discussing Clinical and Payer Insights to Encourage the Adoption of Oncology Biosimilars into Practice

On-Demand Free Accredited Multidisciplinary Panel Discussion

Faculty Panel

Leigh M. Boehmer, PharmD, BCOP
Medical Director
Association of Community Cancer Centers
Rockville, Maryland

Rebecca Borgert, PharmD, BCOP
Senior Director, Oncology Clinical Strategy and Innovation
Magellan Rx Management
Orlando, Florida

Sanjiv S. Agarwala, MD
Professor, Temple University School of Medicine
Philadelphia, Pennsylvania

Chief Medical Officer
Cancer Expert Now, Inc.
Morristown, New Jersey

Medical Writing Support

Lori Huang, BS, PharmD, BCPS
Medical Writer, Clinical Pharmacist
Ann Arbor, Michigan
 
Program Description
The number of available biosimilars on the market for oncology-related indications continues to increase. The manufacturing and development process of biosimilars can be complex, and clinicians may be reluctant to modify prescribing practices or formularies because of these factors. Uncertainty about risks and benefits of oncology biosimilars and their use for either supportive care or treatment has been documented as a barrier to biosimilar uptake. Managed care professionals and pharmacists working with biosimilars need to maintain consistent messaging to both clinicians and patients about their use. The multidisciplinary discussion will cover topics such as extrapolation, interchangeability, and implementation challenges for preferred formulary agents that managed care professionals will encounter when incorporating biosimilars into clinical practice. The panelists will also present strategies and practice guidelines that can be employed to help guide the adoption and optimization of use of oncology biosimilars.

Target Audience:  Managed care and oncology pharmacists
Type of Activity: Application
Release date: August 6, 2021
Expiration date: August 6, 2022
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Classify the core concepts that drive the biosimilar approval process and identify how it differs from the approval of an originator biologic.
• Examine the available and emerging oncology biosimilars, their indications, and their originator biologics.
• Identify clinical and nonclinical barriers that affect the implementation of oncology biosimilars in clinical practice.
• Differentiate the roles of pharmacists, oncologists, and payers in developing strategies to implement oncology biosimilars in clinical practice.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-296-H01-P. The activity is available for CE credit through August 6, 2022.  


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC, and Pharmacy Times Continuing Education™. Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Faculty

Leigh M. Boehmer, PharmD, BCOP, has the following relevant financial relationship with a commercial interest to disclose:

• Consultant: Pfizer

Rebecca Borgert, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

• Consultant: Seagen
• Spouse: Spouse is an employee of Melinta Therapeutics
   

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty
Sanjiv S. Agarwala, MD

Medical Writing Support
Lori Huang, BS, PharmD, BCPS

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy H. Seung, PharmD, BCOP, FHOPA; Kelly McCormick; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers are used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Activity Disclaimer
Pharmacy Times Continuing Education™ (PTCE) strives to provide the highest level of service. However, unforeseen circumstances may necessitate the rescheduling or cancellation of live events, including, but not limited to, webinars hosted by PTCE. PTCE reserves the right to cancel an event without notice. PTCE will not be responsible for any expenditure incurred due to the cancellation.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this live CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms